Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 60505-6050

The provided text represents a survival curve comparison between two treatment groups (VGR-CAP and R-CHOP) for a certain medical condition. The curve shows the percentage of subjects that were still alive during a certain period of time (in months) after receiving treatment. Unfortunately, the numbers and characters in the text do not represent a clear description and cannot be interpreted without more information.*

This text provides detailed information about Bortezomibh, which is a drug manufactured by Apotex Corp. The text includes the ML number, GTIN, and NDC information. The document mentioned the Single Dose Vial where Unused Portion should be discarded. This drug is recommended for intravenous or subcutaneous use. Unfortunately, some parts of the text are not readable or contain unrecognizable characters.*

This is a product description for a medication known as Bortezomib for Injection. It comes in a single-dose vial that has to be discarded if unused. The medication is meant for intravenous or subcutaneous use, and each vial contains 3.5 mg of bortezomib and 35 mg mannitol. This medication is from Apotex Corp., and the reconstitution information is available on the back of the carton or in Section 2 of the Package Insert. The usual dose is indicated in the accompanying Package Insert. It is essential to store it between 20°C to 25°C or 68°F to 77°F, and care should be taken to protect it from light. Finally, the manufacturer is Gland Pharma Limited, India, and manufactured for Apotex Corp. based in Weston, Florida 33326.*

The text presents data related to the effectiveness of Bortezomib medication in treating patients. There is a graph showing the proportion of patients over time and the p-value from the log-rank test. The medication was taken for a period of 360 days, and there were 153 patients involved in the study at the beginning. The number of patients remaining after the indicated time points is not clear. Doxamethasone was also used in the treatment of patients. Overall, the text provides only limited information on the study and its results.*

This is a statistical table showing the proportion of patients who received Bortezomib and Dexamethasone at different time points. The table also includes the number of patients remaining after the indicated time point, and the p-value from a log-rank test.*

This appears to be a survival analysis comparing the VeR-CAP and RCHOP treatments on a group of patients. The Log rank test was applied to the data, and a p-value of less than 0.001 was obtained, indicating a significant difference between the two treatments. The rest of the text may represent a graph showing the survival rates for the two groups over a period of time.*

This text appears to be a calculation formula for determining the appropriate dosage of bortezomib for injection based on the patient's body surface area. The formula requires the Bortezomib dose in mg/m2 and the patient's body surface area in square meters to calculate the total volume of bortezomib for injection (in mL) to administer.*

Bortezomib is a medication used for intravenous and subcutaneous injection, available in 1mg/mL concentration. It is recommended to read the full instructions in the package insert (Section 2) before use. The vial has a sticker indicating the method of injection and volume of salt solution to be added to make the final reconstitution.*

This text is a dosage calculation formula for Bortezomib, a medication used in the treatment of cancer. The formula is used to determine the total volume of the medication that should be administered to a patient based on their body surface area (BSA) and the prescribed dose of Bortezomib per meter square (mg/m2). It is important for healthcare providers to use accurate measurements and follow dosage guidelines to ensure patient safety and treatment efficacy.*